Abstract

We analysed the clinical and pathologic features of 42 patients with immunologically confirmed peripheral T‐cell lymphoma. The median age was 60 years and the male to female ratio was 1:1. A prior lymphoprolifera‐tive or autoimmune disorder was present in 14 per cent of the patients. Signs of advanced disease were usually present from the onset, such as B symptoms (55 per cent), generalized lymphadenopathy (57 per cent), stage III/IV disease (62 per cent), and elevated levels of serum lactate dehydrogenase (68 per cent). Primary extranodal disease (14 per cent), hepatomegaly (12 per cent), splenomegaly (12 per cent), lung/pleural involvement (12 per cent), skin involvement (21 per cent), and bone marrow involvement (28 per cent) were uncommon. Lymphocytopenia was present in 64 per cent of the patients, and none of nine patients tested were serologically positive for human T‐cell leukemia/lymphoma virus (HTLV‐I) infection. Among 38 patients receiving combination chemotherapy, 20 (53 per cent) achieved a complete remission. The actuarial median survival of all patients was 17 months. Age greater than 60 years and stage III/IV disease predicted a poor clinical outcome, whereas the large cell histological subtype predicted a favourable outcome. Prospective clinical studies using uniform treatments and a uniform histologic classification scheme are needed to confirm these findings.

Original languageEnglish (US)
Pages (from-to)175-187
Number of pages13
JournalHematological Oncology
Volume5
Issue number3
DOIs
StatePublished - Jul 1987

Fingerprint

Lymphoma
Lymphopenia
Hepatomegaly
Splenomegaly
Virus Diseases
Combination Drug Therapy
L-Lactate Dehydrogenase
Leukemia
Bone Marrow
Prospective Studies
Lung
Skin
Survival
Serum
Therapeutics

Keywords

  • Malignant lymphoma
  • Non‐Hodgkin's lymphoma
  • Peripheral T‐cell lymphoma
  • T‐cell

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Peripheral T‐cell lymphoma : A clinicopathologic study of 42 cases. / Weisenburger, D. D.; Linder, James; Armitage, James Olen.

In: Hematological Oncology, Vol. 5, No. 3, 07.1987, p. 175-187.

Research output: Contribution to journalArticle

@article{356c754fe08d445db4623d6a75cba81c,
title = "Peripheral T‐cell lymphoma: A clinicopathologic study of 42 cases",
abstract = "We analysed the clinical and pathologic features of 42 patients with immunologically confirmed peripheral T‐cell lymphoma. The median age was 60 years and the male to female ratio was 1:1. A prior lymphoprolifera‐tive or autoimmune disorder was present in 14 per cent of the patients. Signs of advanced disease were usually present from the onset, such as B symptoms (55 per cent), generalized lymphadenopathy (57 per cent), stage III/IV disease (62 per cent), and elevated levels of serum lactate dehydrogenase (68 per cent). Primary extranodal disease (14 per cent), hepatomegaly (12 per cent), splenomegaly (12 per cent), lung/pleural involvement (12 per cent), skin involvement (21 per cent), and bone marrow involvement (28 per cent) were uncommon. Lymphocytopenia was present in 64 per cent of the patients, and none of nine patients tested were serologically positive for human T‐cell leukemia/lymphoma virus (HTLV‐I) infection. Among 38 patients receiving combination chemotherapy, 20 (53 per cent) achieved a complete remission. The actuarial median survival of all patients was 17 months. Age greater than 60 years and stage III/IV disease predicted a poor clinical outcome, whereas the large cell histological subtype predicted a favourable outcome. Prospective clinical studies using uniform treatments and a uniform histologic classification scheme are needed to confirm these findings.",
keywords = "Malignant lymphoma, Non‐Hodgkin's lymphoma, Peripheral T‐cell lymphoma, T‐cell",
author = "Weisenburger, {D. D.} and James Linder and Armitage, {James Olen}",
year = "1987",
month = "7",
doi = "10.1002/hon.2900050304",
language = "English (US)",
volume = "5",
pages = "175--187",
journal = "Hematological Oncology",
issn = "0278-0232",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Peripheral T‐cell lymphoma

T2 - A clinicopathologic study of 42 cases

AU - Weisenburger, D. D.

AU - Linder, James

AU - Armitage, James Olen

PY - 1987/7

Y1 - 1987/7

N2 - We analysed the clinical and pathologic features of 42 patients with immunologically confirmed peripheral T‐cell lymphoma. The median age was 60 years and the male to female ratio was 1:1. A prior lymphoprolifera‐tive or autoimmune disorder was present in 14 per cent of the patients. Signs of advanced disease were usually present from the onset, such as B symptoms (55 per cent), generalized lymphadenopathy (57 per cent), stage III/IV disease (62 per cent), and elevated levels of serum lactate dehydrogenase (68 per cent). Primary extranodal disease (14 per cent), hepatomegaly (12 per cent), splenomegaly (12 per cent), lung/pleural involvement (12 per cent), skin involvement (21 per cent), and bone marrow involvement (28 per cent) were uncommon. Lymphocytopenia was present in 64 per cent of the patients, and none of nine patients tested were serologically positive for human T‐cell leukemia/lymphoma virus (HTLV‐I) infection. Among 38 patients receiving combination chemotherapy, 20 (53 per cent) achieved a complete remission. The actuarial median survival of all patients was 17 months. Age greater than 60 years and stage III/IV disease predicted a poor clinical outcome, whereas the large cell histological subtype predicted a favourable outcome. Prospective clinical studies using uniform treatments and a uniform histologic classification scheme are needed to confirm these findings.

AB - We analysed the clinical and pathologic features of 42 patients with immunologically confirmed peripheral T‐cell lymphoma. The median age was 60 years and the male to female ratio was 1:1. A prior lymphoprolifera‐tive or autoimmune disorder was present in 14 per cent of the patients. Signs of advanced disease were usually present from the onset, such as B symptoms (55 per cent), generalized lymphadenopathy (57 per cent), stage III/IV disease (62 per cent), and elevated levels of serum lactate dehydrogenase (68 per cent). Primary extranodal disease (14 per cent), hepatomegaly (12 per cent), splenomegaly (12 per cent), lung/pleural involvement (12 per cent), skin involvement (21 per cent), and bone marrow involvement (28 per cent) were uncommon. Lymphocytopenia was present in 64 per cent of the patients, and none of nine patients tested were serologically positive for human T‐cell leukemia/lymphoma virus (HTLV‐I) infection. Among 38 patients receiving combination chemotherapy, 20 (53 per cent) achieved a complete remission. The actuarial median survival of all patients was 17 months. Age greater than 60 years and stage III/IV disease predicted a poor clinical outcome, whereas the large cell histological subtype predicted a favourable outcome. Prospective clinical studies using uniform treatments and a uniform histologic classification scheme are needed to confirm these findings.

KW - Malignant lymphoma

KW - Non‐Hodgkin's lymphoma

KW - Peripheral T‐cell lymphoma

KW - T‐cell

UR - http://www.scopus.com/inward/record.url?scp=0023374734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023374734&partnerID=8YFLogxK

U2 - 10.1002/hon.2900050304

DO - 10.1002/hon.2900050304

M3 - Article

C2 - 2888715

AN - SCOPUS:0023374734

VL - 5

SP - 175

EP - 187

JO - Hematological Oncology

JF - Hematological Oncology

SN - 0278-0232

IS - 3

ER -